Therapeutic Drug Monitoring Market Size, Share, Industry Trends, and Growth Forecasts, 2026-2031 | Precision Dosing and Wearables Drive 9.03% CAGR Toward USD 2.29 Billion
Dublin, Oct. 06, 2026 (GLOBE NEWSWIRE) -- "Therapeutic Drug Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
Therapeutic Drug Monitoring Market to Reach USD 2.29 Billion by 2031
The global therapeutic drug monitoring market was valued at USD 1.36 billion in 2025 and is projected to increase from USD 1.48 billion in 2026 to USD 2.29 billion by 2031. The market is expected to record a CAGR of 9.03% during the forecast period of 2026-2031, supported by rising demand for personalized dosing, precision medicine, advanced diagnostic technologies, and improved drug-safety management.
Rising Disease Burden Strengthens Demand for Therapeutic Drug Monitoring
The increasing prevalence of cancer, HIV, autoimmune disorders, and cardiovascular diseases is creating sustained demand for therapeutic drug monitoring. Cancer treatment protocols increasingly combine small-molecule kinase inhibitors with monoclonal antibodies, creating narrow therapeutic margins that require precise serum-level control. Accurate monitoring helps clinicians maintain treatment effectiveness while reducing dose-limiting toxicity.
Long-acting cabotegravir-rilpivirine combinations used in HIV treatment are expanding monitoring requirements beyond daily oral therapies. These regimens require confirmation of sustained trough concentrations over monthly or bi-monthly intervals. Autoimmune diseases are also frequently treated with biologic agents whose clearance rates may vary because of anti-drug antibody formation. Therapeutic drug monitoring can help distinguish primary non-response from immunogenic loss of efficacy and support informed treatment adjustments.
Aging populations are contributing to higher demand for digoxin and antiarrhythmic drug-level testing. Careful monitoring can reduce the risk of treatment-related toxicity while supporting safer cardiovascular care. Together, these clinical applications are expected to generate predictable growth in testing volumes.
Clinical Trials and Companion Diagnostics Support Market Expansion
Regulatory expectations for dose-optimization evidence across varied genotypes and comorbidity profiles are embedding therapeutic drug monitoring into clinical trial protocols. Drug developers are increasingly combining LC-MS/MS analytics with pharmacogenomic algorithms to support adaptive dosing and reduce late-stage clinical development risks.
Decentralized trials are also encouraging the use of mailed dried-blood-spot sampling kits, enabling reliable data collection while reducing the need for site visits. Evidence generated during clinical trials can subsequently support post-marketing label expansions that include serum-level guidance, increasing routine demand for assays and laboratory services.
High Platform Costs Remain a Key Market Restraint
The cost of LC-MS/MS systems continues to limit adoption, particularly among secondary hospitals and private laboratories in low- and middle-income economies. Entry-level triple-quadrupole platforms can cost USD 300,000-500,000, while annual maintenance contracts may add approximately USD 50,000. Even laboratories in developed markets must demonstrate sufficient utilization before receiving purchase approval.
These financial barriers often result in continued reliance on external testing services, which can increase turnaround times and reduce immediate clinical value. Pooled-purchasing programs and reagent-rental models may ease cash-flow constraints, but many facilities still depend on immunoassays. This dependence can restrict cross-reactivity-sensitive applications involving kinase inhibitors and immunotherapies. Additional market constraints include shortages of skilled clinical toxicologists in emerging economies.
Technology Trends Reshape Testing Workflows
Immunoassays accounted for 58.74% of therapeutic drug monitoring market revenue in 2025. Their leadership is supported by integration with established chemistry systems, consistent reimbursement practices, and laboratory staff familiarity. Automation and high-throughput immunoassay adoption in core laboratories are expected to reinforce this position.
Biosensor-based and wearable platforms are forecast to record a 9.74% CAGR, driven by electrochemical advances that enable in-situ drug-level measurements from interstitial fluid. Continuous wearables under development could offer sub-minute sampling intervals, shifting therapeutic drug monitoring from periodic blood collection toward dynamic pharmacokinetic assessment. Future adoption will depend on usability, data-security architecture, regulatory clarity, and the effectiveness of algorithmic dosing guidance.
Protein-binding interference, hook effects, and cross-reactivity are also encouraging tertiary medical centers to adopt chromatographic and LC-MS/MS solutions for complex treatment regimens. Mass-spectrometry-linked immunochemical technologies are broadening test menus to include small-molecule oncology therapies, while low-cost dried-blood-spot sampling is improving access to remote therapeutic drug monitoring.
Regional Therapeutic Drug Monitoring Market Outlook
North America held 41.80% of the global market in 2025, supported by established reimbursement systems, extensive transplant programs, and leadership in pharmacogenomics. Europe demonstrates similarly mature adoption, although cost-containment measures continue to encourage consolidated procurement and outcome-based pricing.
Asia-Pacific is projected to expand at a 10.27% CAGR through 2031, making it a major growth region. Hospital construction, clinical-trial investment, and national precision-health initiatives are increasing demand for advanced monitoring technologies. China is benefiting from public-sector infrastructure funding and local LC-MS/MS manufacturing, while Japan's super-aged population supports high per-capita testing rates. In India, broader health-insurance coverage is improving access to essential monitoring panels. The Middle East and South America are also recording growing adoption as laboratory automation initiatives modernize diagnostic infrastructure.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising prevalence of oncology, HIV, autoimmune & cardiac cases
4.2.2 Expansion of clinical trials & companion-diagnostic mandates
4.2.3 Automation & high-throughput immunoassay adoption in core labs
4.2.4 Low-cost dried-blood-spot sampling enabling remote TDM
4.2.5 Integration of pharmacogenomic data with TDM algorithms
4.2.6 Wearable micro-fluidic biosensors for real-time drug-level tracking
4.3 Market Restraints
4.3.1 Capital & service-contract costs of LC-MS/MS platforms
4.3.2 Shortage of skilled clinical toxicologists in emerging nations
4.3.3 Fragmented reimbursement coding for TDM panels
4.3.4 Data-exchange gaps between LIS & decision-support software
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitute Products
4.7.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value - USD million)
5.1 By Technology
5.1.1 Immunoassays
5.1.1.1 ELISA
5.1.1.2 Chemiluminescence Immunoassay (CLIA)
5.1.1.3 Fluorescence & Other IA Formats
5.1.2 Proteomic / LC-MS/MS
5.1.3 Chromatography (GC, HPLC)
5.1.4 Biosensor-Based & Wearables
5.1.5 Other Technologies
5.2 By Drug Class
5.2.1 Antiarrhythmic Drugs
5.2.2 Antiepileptic Drugs
5.2.3 Immunosuppressants
5.2.4 Antibiotics (e.g., Vancomycin, Aminoglycosides)
5.2.5 Antipsychotics & Mood Stabilizers
5.2.6 Oncology & Targeted Therapies
5.2.7 Other Drug Classes
5.3 By End-user
5.3.1 Hospital Laboratories
5.3.2 Independent / Reference Laboratories
5.3.3 Academic & Research Institutes
5.3.4 Point-of-Care / Patient Self-Testing
5.3.5 Contract Research & CRO Labs
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 South Korea
5.4.3.5 Australia
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
6.3.1 Abbott Laboratories
6.3.2 Thermo Fisher Scientific
6.3.3 F. Hoffmann-La Roche Ltd (Roche Diagnostics)
6.3.4 Siemens Healthineers
6.3.5 Danaher Corp (Beckman Coulter)
6.3.6 Bio-Rad Laboratories
6.3.7 Chromsystems Instruments & Chemicals
6.3.8 Randox Laboratories
6.3.9 Alpco Diagnostics
6.3.10 ARK Diagnostics
6.3.11 DiaSorin S.p.A.
6.3.12 bioMerieux SA
6.3.13 Tecan Group
6.3.14 Waters Corporation
6.3.15 Agilent Technologies
6.3.16 Hitachi High-Tech Corp.
6.3.17 Bruker Corp.
6.3.18 JEOL Ltd.
6.3.19 Quotient Ltd.
6.3.20 LabCorp (Covance Labs)
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/orhx8x
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.